MatErnal BLood IS Source to Accurately Diagnose Fetal Aneuploidy

Completed

Conditions studied: Pregnant Women, Prenatal Care

In brief

The primary objective of this study is to determine the performance characteristics (sensitivity and specificity) of the Verinata Health Test to detect fetal Trisomy 21 (T21) compared to karyotype results obtained by amniocentesis or chorionic villus sampling (CVS). Secondary objectives are to assess performance of the test to detect male gender (XY) and other less common aneuploidies (Trisomy 13 (T13), Trisomy 18 (T18), and Turner Syndrome (45, X)) compared to clinical fetal karyotype.

Key facts

Study ID
NCT01122524
Run by
Verinata Health, Inc.
People needed
10000
Starts
2010-06-01
Expected to finish
2011-10-01
Last updated by the study team
2011-10-10

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.